30.11.2012 - Selecta Biosciences and Sanofi have signed a global collaboration to develop antigen-specific immunotherapies for up to three allergy indications.
The US-based biotech has developed a synthetic vaccine particle technology which is now being licensed to the French pharma for up to US$900m including a number of milestone payments. The agreement gives Sanofi the right to develop a therapy to fight an immune response triggered by a life-threatening food allergen. Furthermore, Sanofi may develop two other compounds. The pharma got in touch following the lure of the technology discovered in the lab of Bob Langer at the MIT.
Selecta engineers nanoparticles with the structure required to stimulate immune tolerance thereby controlling overactive response to antigens. Selecta won substantial backing from RusNano last autumn, agreeing to set up operations in Russia as part of the deal. Privately held Selecta is a shooting star since its foundation in 2008, raising more than US-$32m in three venture rounds, finally attracting the attention of Rusnano. Last year, the US$10bn Russian fund joined Selecta’s existing investor base. The consortium spent US$47.25m to broaden the company’s R&D capabilities and accelerate its pipeline of vaccines and immunotherapies.
23.07.2014 In the largest genomic study published on any psychiatric disorder so far, researchers have indentified 83 new locations in the human genome associated with the risk of developing schizophrenia.
15.07.2014 British specialty pharma company Prostrakan is handing over £230m for Archimedes Pharma Limited, a company that brings its lead product Pecfent and its proprietary drug delivery technology platform into the deal.
11.07.2014 Among the seven newly launched Joint Technology Initiatives (JTI) of Horizon2020 are two with deep roots in biotech: IMI is going into its second round while the newly established Bio-based Industries partnership invests in bioeconomy.